Between 1993 and 2003, four acetylcholinesterase inhibitors and memantine were licensed in the USA and Europe for the symptomatic treatment of Alzheimer’s disease [1, 2]. This evidence concerns the gene ACHE and early-onset autosomal dominant Alzheimer disease.